<DOC>
	<DOCNO>NCT01248130</DOCNO>
	<brief_summary>The primary aim study examine efficacy tolerability short-term omega-3 fatty acid monotherapy youth Autism Spectrum Disorders ( ASD ) . The investigator hypothesize Omega-3 fatty acid efficacious improve core associate feature ASD youth , Omega-3 fatty acid monotherapy safe well tolerate youth ASD . The secondary aim study examine neuropsychological effect Omega-3 fatty acid monotherapy youth ASD . The investigator hypothesize omega-3 fatty acid efficacious improve cognitive function youth ASD .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Monotherapy Children Adolescents With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Inclusion 1 . Male female participant 6 17 year age , inclusive . 2 . Fulfills diagnosis autism spectrum disorder meet DSMIVTR PDD diagnostic criterion autistic disorder , Asperger 's disorder , PDDNOS establish clinical interview assist MGH PDD Symptom Checklist . 3 . Participants least moderate symptom severity ASD reflect SRS score ≥ 85 CGIPDD severity score ≥ 4 ( moderately ill ) . 4 . Subjects must psychotropic drugfree minimum four week prior baseline visit . 5 . Subjects mood , anxiety , disruptive behavior disorder allow participate study provide meet exclusionary criterion . Exclusion 1 . I.Q . &lt; 85 . 2 . DSMIVTR PDD diagnose Rett 's disorder , childhood disintegrative disorder . 3 . Current diagnosis psychotic disorder unstable mood anxiety disorder determine clinician . 4 . Subject marked severity symptom suggest score ≥ 5 ( markedly ill ) CGI severity subscale respective comorbid psychiatric disorder . 5 . Clinically unstable psychiatric condition judge serious risk self others determine clinician . 6 . History substance use ( except nicotine caffeine ) within past 3 month , determine clinically significant clinician . 7 . Urine drug screen positive substance abuse . 8 . Nonfebrile seizure without clear resolve etiology last month . 9 . Subjects medical condition treatment either jeopardize subject safety affect scientific merit study , include : 1 . Pregnant nursing female ; 2 . Organic brain disorder ; 3 . Uncorrected hypothyroidism hyperthyroidism , determine study clinician ; 4 . Untreated and/or unstable diabetes ; 5 . Subjects clinically significant abnormality accord cardiology consultation ( ECGs clinically concern interval include PR , QTC , QRS , review cardiology ) . 6 . History renal hepatic impairment determine clinically significant clinician . 10 . Serious , unstable systemic illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease , determine clinician . 11 . Any concomitant medication primary central nervous system activity specify Concomitant Medication section protocol . 12 . Subjects difficulty swallow pill . 13 . History know allergy Omega3 fatty acid , multiple drug allergy , severe allergy . 14 . A nonresponder , history intolerance Omega3 fatty acid , treatment adequate dose duration determine clinician .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Omega-3 Fatty Acid</keyword>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Pervasive Developmental Disorders</keyword>
	<keyword>Children</keyword>
	<keyword>Cognitive Functioning</keyword>
</DOC>